U.S. Markets open in 6 hrs 47 mins
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,780.30
    +2.10 (+0.12%)
     
  • Silver

    22.53
    -0.04 (-0.17%)
     
  • EUR/USD

    1.1726
    -0.0004 (-0.0352%)
     
  • 10-Yr Bond

    1.3240
    0.0000 (0.00%)
     
  • Vix

    24.36
    -1.35 (-5.25%)
     
  • GBP/USD

    1.3647
    -0.0017 (-0.1242%)
     
  • USD/JPY

    109.5920
    +0.3720 (+0.3406%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,051.38
    -12.46 (-1.17%)
     
  • FTSE 100

    6,980.98
    +77.07 (+1.12%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Why Curis (CRIS) Shares Are Surging Today?

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Curis Inc (NASDAQ: CRIS) shares are surging in reaction to updated data from its ongoing open-label, single-arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS).

  • As of data cut off on February 8, in 15 patients (8 MDS and 7 AML), four objective responses were recorded with signs of hematologic recovery, including:

    • One complete response (CR), one complete remission with incomplete hematologic recovery (CRi) with negative minimal residual disease, and two bone marrow CRs.

    • All three patients with SF3B1 or U2AF1 spliceosome mutation achieved marrow CR or better.

  • The company said that two abstracts with updated data would be presented at the upcoming European Hematology Association 2021 Virtual Congress to be held next month.

  • CA-4948 is an IRAK4 kinase inhibitor, and IRAK4 plays an essential role in the toll-like receptor and interleukin-1 receptor signaling pathways, which are frequently dysregulated in patients with AML and MDS.

  • Cantor Fitzgerald analyst Alethia Young views Curis's abstract update as highly encouraging with more patients and longer follow-up, the analyst tells investors in a research note.

  • The analyst made no changes to the firm's Overweight ratings and thinks the initial look from the abstracts appears very positive.

  • Last month, CA-4948 received FDA's Orphan Drug designation in AML and MDS.

  • Price Action: CRIS shares rose 60.8% at $15.79 during the market session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.